Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adsorbizumab plus irinotecan liposomes in extensive-stage small cell lung cancer after first-line progression
ChiCTR2400089170Phase 2Not yet recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of adebrelimab and nanoliposomal irinotecan in small cell lung cancer (SCLC) (2 cohorts), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Overall response rate. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
adebrelimabnanoliposomal irinotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2400089170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089170.